Safety and Efficacy Study of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet)
Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety and efficacy of PN2034 administered to type 2
diabetics on concomitant rosiglitazone and metformin (or Avandamet) therapy as measured by
change in glycosylated hemoglobin (HbA1c) levels from baseline to Week 12. Also the study
will evaluate the effect of PN2034 on glucose control as measured by fasting plasma glucose
(FPG) and on fasting lipid levels: triglycerides, total cholesterol, high-density
lipoproteins (HDL), low-density lipoproteins (LDL), and very low-density lipoproteins (VLDL).